{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:16:57Z","timestamp":1772749017618,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,6,25]],"date-time":"2011-06-25T00:00:00Z","timestamp":1308960000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s10549-011-1637-5","type":"journal-article","created":{"date-parts":[[2011,6,25]],"date-time":"2011-06-25T15:19:29Z","timestamp":1309015169000},"page":"947-953","source":"Crossref","is-referenced-by-count":22,"title":["MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU\/epirubicin\/cyclophosphamide"],"prefix":"10.1007","volume":"132","author":[{"given":"Masatsugu","family":"Okishiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Tsunashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Shimazu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinzaburo","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,25]]},"reference":[{"key":"1637_CR1","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","volume":"24","author":"H Roche","year":"2006","unstructured":"Roche H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24:5664\u20135671","journal-title":"J Clin Oncol"},{"key":"1637_CR2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3816\/CBC.2004.n.035","volume":"5","author":"MA Mouret-Reynier","year":"2004","unstructured":"Mouret-Reynier MA, Abrial CJ, Ferri\u00e8re JP et al (2004) Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin. Clin Breast Cancer 5:303\u2013307","journal-title":"Clin Breast Cancer"},{"key":"1637_CR3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2001.19.3.602","volume":"19","author":"French Adjuvant Study Group","year":"2001","unstructured":"French Adjuvant Study Group (2001) Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5\u00a0year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602\u2013611","journal-title":"J Clin Oncol"},{"key":"1637_CR4","first-page":"1483","volume":"37","author":"H Abe","year":"2010","unstructured":"Abe H, Umeda T, Tanaka M et al (2010) Feasibility of FEC 100 followed by DOC 100 as adjuvant chemotherapy for breast cancer. Gan To Kagaku Ryoho 37:1483\u20131487","journal-title":"Gan To Kagaku Ryoho"},{"key":"1637_CR5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-007-9744-z","volume":"110","author":"M Toi","year":"2008","unstructured":"Toi M, Nakamura S, Kuroi K et al (2008) Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110:531\u2013539","journal-title":"Breast Cancer Res Treat"},{"key":"1637_CR6","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.1158\/0008-5472.CAN-06-4533","volume":"67","author":"MS Nayak","year":"2007","unstructured":"Nayak MS, Yang JM, Hait WN (2007) Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res 67:5831\u20135839","journal-title":"Cancer Res"},{"key":"1637_CR7","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1158\/1078-0432.CCR-05-0173","volume":"11","author":"J Tommiska","year":"2005","unstructured":"Tommiska J, Eerola H, Heinonen M et al (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098\u20135103","journal-title":"Clin Cancer Res"},{"key":"1637_CR8","doi-asserted-by":"crossref","first-page":"7328","DOI":"10.1158\/1078-0432.CCR-05-0507","volume":"11","author":"Y Xu","year":"2005","unstructured":"Xu Y, Yao L, Ouyang T et al (2005) p53 codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11:7328\u20137333","journal-title":"Clin Cancer Res"},{"key":"1637_CR9","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/ijc.23454","volume":"122","author":"Y Xu","year":"2008","unstructured":"Xu Y, Yao L, Zhao A et al (2008) Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. Int J Cancer 122:2761\u20132766","journal-title":"Int J Cancer"},{"key":"1637_CR10","doi-asserted-by":"crossref","first-page":"R34","DOI":"10.1186\/bcr1682","volume":"9","author":"T Toyama","year":"2007","unstructured":"Toyama T, Zhang Z, Nishio M et al (2007) Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9:R34","journal-title":"Breast Cancer Res"},{"key":"1637_CR11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ng1093","volume":"33","author":"P Dumont","year":"2003","unstructured":"Dumont P, Leu JI, Della Pietra AC 3rd, George D, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357\u2013365","journal-title":"Nat Genet"},{"key":"1637_CR12","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1038\/sj.onc.1207428","volume":"23","author":"A Sullivan","year":"2004","unstructured":"Sullivan A, Syed N, Gasco M et al (2004) Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23:3328\u20133337","journal-title":"Oncogene"},{"key":"1637_CR13","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1186\/bcr2460","volume":"11","author":"MK Schmidt","year":"2009","unstructured":"Schmidt MK, Tommiska J, Broeks et al (2009) Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res 11:R89","journal-title":"Breast Cancer Res"},{"key":"1637_CR14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/jnci\/djj245","volume":"98","author":"BJ Boersma","year":"2006","unstructured":"Boersma BJ, Howe TM, Goodman JE et al (2006) Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98:911\u2013919","journal-title":"J Natl Cancer Inst"},{"key":"1637_CR15","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205","journal-title":"J Clin Oncol"},{"key":"1637_CR16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.1440-1827.2002.01327.x","volume":"52","author":"H Tsuda","year":"2002","unstructured":"Tsuda H, Sasano H, Akiyama F et al (2002) Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2\/neu (c-erbB-2) expression detected by herceptest, nichirei polyclonal antibody, CB11 and TAB 250 in breast carcinoma. Pathol Int 52:126\u2013134","journal-title":"Pathol Int"},{"key":"1637_CR17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403\u2013410","journal-title":"Histopathology"},{"key":"1637_CR18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/tpj.2009.45","volume":"10","author":"AV Khrunin","year":"2010","unstructured":"Khrunin AV, Moisseev A, Gorbunova V, Limborska S (2010) Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 10:54\u201361","journal-title":"Pharmacogenomics J"},{"key":"1637_CR19","first-page":"4285","volume":"57","author":"PM O\u2019Connor","year":"1997","unstructured":"O\u2019Connor PM, Jackman J, Bae I et al (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285\u20134300","journal-title":"Cancer Res"},{"key":"1637_CR20","first-page":"50","volume":"6","author":"D Kandioler-Eckersberger","year":"2000","unstructured":"Kandioler-Eckersberger D, Ludwig C, Rudas M et al (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6:50\u201356","journal-title":"Clin Cancer Res"},{"key":"1637_CR21","doi-asserted-by":"crossref","first-page":"e3062","DOI":"10.1371\/journal.pone.0003062","volume":"26","author":"R Chrisanthar","year":"2008","unstructured":"Chrisanthar R, Knappskog S, L\u00f8kkevik E et al (2008) CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 26:e3062","journal-title":"PLoS One"},{"key":"1637_CR22","first-page":"2505","volume":"6","author":"S Geisler","year":"2001","unstructured":"Geisler S, L\u00f8nning PE, Aas T et al (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 6:2505\u20132512","journal-title":"Cancer Res"},{"key":"1637_CR23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1172\/JCI6863","volume":"104","author":"F Bunz","year":"1999","unstructured":"Bunz F, Hwang PM, Torrance C et al (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263\u2013269","journal-title":"J Clin Invest"},{"key":"1637_CR24","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1371\/journal.pmed.0040090","volume":"4","author":"P Bertheau","year":"2007","unstructured":"Bertheau P, Turpin E, Rickman DS et al (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4:e90","journal-title":"PLoS Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1637-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-011-1637-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1637-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:33:49Z","timestamp":1559234029000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-011-1637-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,25]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["1637"],"URL":"https:\/\/doi.org\/10.1007\/s10549-011-1637-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,25]]}}}